Table 3.
Univariate and multivariate analyses for predicting renal replacement therapy
| Variable | Univariate analysis |
Multivariate analysis |
||
|---|---|---|---|---|
| OR (95% CI) | p value | OR (95% CI) | p value | |
| Age | 2.28 (0.18–28.71) | 0.523 | ||
| Sex | 0.153 (0.023–1.036) | 0.054 | 0.198 (0.039–1.011) | 0.072 |
| DM | 0.355 (0.052–2.404) | 0.289 | ||
| HTN | 1.991 (0.532–7.449) | 0.305 | ||
| CKD | 8.257 (0.868–78.532) | 0.066 | ||
| Severity of AKI (vs. stage 1 and stage 2) | ||||
| KDIGO stage 3 | 25.11 (1.86–58.05) | 0.001 | 17.86 (1.20–265.49) | < 0.005 |
| Baseline eGFR | 1.049 (0.971–1.010) | 0.941 | ||
| Baseline serum creatinine | 1.039 (0.737–1.464) | 0.829 | ||
| Admission serum creatinine | 1.512 (1.094–2.090) | 0.012 | ||
| Urine NGAL/Cr | 1.035 (1.003–1.067) | 0.030 | ||
| Urine KIM-1/Cr | 1.008 (0.996–1.021) | 0.208 | ||
| Urine TIMP-2/IGFBP7 (vs. 1st and 2nd quartile group) | ||||
| 3rd Quartile group | 8.48 (0.735–97.77) | 0.087 | 5.75 (0.67–49.48) | 0.011 |
| 4th Quartile group | 79.75 (5.19–1,225.37) | 0.002 | 44.98 (4.40–460.29) | 0.001 |
In the multivariate analysis model, a backward (LR) selection approach was adopted.
OR, odds ratio; CI, confidence interval; DM, diabetes mellitus; HTN, hypertension; CKD, chronic kidney disease; AKI, acute kidney injury; KDIGO, Kidney Disease Improving Global Outcomes; eGFR, estimate glomerular filtration rate; NGAL, neutrophil gelatinase-associated lipocalin; Cr, creatinine; KIM-1, kidney injury molecule 1; TIMP-2, tissue inhibitor of metalloproteinase-2; IGFBP7, insulin-like growth factor-binding protein 7.